Targeting key steps in metastatic tumour progression

被引:63
作者
Eccles, SA [1 ]
机构
[1] Inst Canc Res, McElwain Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
关键词
D O I
10.1016/j.gde.2004.12.001
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The key determinants of tumour progression and discriminators of benign and malignant lesions include neoangiogenesis (the induction of a new blood supply) and the capacity of malignant cells to invade and metastasise. It is now recognized that these processes can be co-ordinately regulated by the activity of specific genes - often distinct from those involved in early oncogenesis - and involve common signalling pathways. Cell motility and chemotaxis (the ability to respond to gradients of chemoattractants) are implicated in both tumour-cell invasion and response of activated endothelial cells to angiogenic cytokines, and provide interesting and novel points for therapeutic intervention.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 64 条
[31]   HSP90 as a new therapeutic target for cancer therapy: the story unfolds [J].
Maloney, A ;
Workman, P .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (01) :3-24
[32]   DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling [J].
Mamoune, A ;
Kassis, J ;
Kharait, S ;
Kloeker, S ;
Manos, E ;
Jones, DA ;
Wells, A .
EXPERIMENTAL CELL RESEARCH, 2004, 299 (01) :91-100
[33]   Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK) [J].
Manetti, F ;
Botta, M .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (07) :567-581
[34]   Memo mediates ErbB2-driven cell motility [J].
Marone, R ;
Hess, D ;
Dankort, D ;
Muller, WJ ;
Hynes, NE ;
Badache, A .
NATURE CELL BIOLOGY, 2004, 6 (06) :515-522
[35]   Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis [J].
Mazure, NM ;
Brahimi-Horn, MC ;
Pouysségur, J .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (07) :531-541
[36]   Recruitment and activation of phospholipase Cγ1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells [J].
Meyer, RD ;
Latz, C ;
Rahimi, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (18) :16347-16355
[37]   Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation [J].
Mouneimne, G ;
Soon, L ;
DesMarais, V ;
Sidani, M ;
Song, XY ;
Yip, SC ;
Ghosh, M ;
Eddy, R ;
Backer, JM ;
Condeelis, J .
JOURNAL OF CELL BIOLOGY, 2004, 166 (05) :697-708
[38]   Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway [J].
Nakashio, A ;
Fujita, N ;
Tsuruo, T .
INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (01) :36-41
[39]   Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth [J].
Noren, NK ;
Lu, M ;
Freeman, AL ;
Koolpe, M ;
Pasquale, EB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (15) :5583-5588
[40]   A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops [J].
O-Charoenrat, P ;
Rhys-Evans, P ;
Eccles, S .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (05) :527-533